WeightWatchers rises on higher Q2 clinical subscription revenue

** Shares of telehealth firm WW International WW.O rise 8.5% to $41.50 premarket

** Co, also known as WeightWatchers, reports its clinical subscription revenue rose 55.1% during the quarter ended June 30, driven by compounded semaglutide subscriptions

** Says from May 22, it began transitioning subscribers from compounded semaglutide to FDA-approved medications, in line with current FDA guidance

** Co, forecasts 2025 total revenue to be in the range of $685 million to $700 million

** Forecasts adj. core profit to be in the range of $140 million to $150 million

** Co has not previously provided a forecast for 2025